SUMMARY Plasma free captopril concentrations and haemodynamic response to captopril were studied in 20 patients with severe chronic heart failure. A 25 mg oral dose of captopril produced a 36% reduction in systemic vascular resistance, with individual responses varying from 13% to 64%. Mean systemic pressure fell by 200% and cardiac output rose 28%. The absorption of captopril was rapid. Peak plasma free captopril concentration occurred at 45 minutes after the dose and was followed by a smaller second peak. Peak plasma free captopril concentrations varied more than 20-fold but did not correlate with the maximal reduction in systemic vascular resistance. Elimination half life was seven hours. Fourteen patients were restudied after 1-2 months of captopril treatment and 12 showed symptomatic benefit. There was a sustained improvement in haemodynamic state and in non-invasive indices of myocardial function. During long term treatment the predose plasma free captopril concentration correlated well with dosage, but steady state captopril concentrations did not show a significant relation with haemodynamic response. On a dosage regimen of 25-50 mg three times daily the morning predose plasma free captopril concentration and plasma renin activity were relatively low and suggested that maximal inhibition of the renin-angiotensin system was not maintained throughout the dosage interval.
Captopril, a vasodilator which acts by inhibiting conversion of angiotensin I to angiotensin II, has been shown to benefit patients with chronic severe heart failure. 1 The response to captopril varies appreciably between subjects, but the reasons for this are not fully understood. Measurement of plasma concentrations of captopril has been difficult because of the highly reactive thiol group in the captopril molecule. A radioimmunoassay for captopril has been developed,2 using antibodies to a captopril-N-ethylmaleimide complex, and we have used this assay to study the relation between plasma free captopril concentrations, haemodynamic responses, and plasma renin activity.
Patients and methods

STUDY POPULATION
Twenty patients (mean age 62-4 (range 47-71) years) were studied, all of whom had severe left ventricular
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Accepted for publication 19 March 1985 myocardial impairment due to ischaemic heart disease in 13 For the radioimmunoassay of captopril 10 mg N-ethylmaleimide was added to 5 ml plasma separated in a refrigerated centrifuge immediately after withdrawal of the blood sample. The radioimmunoassay technique has been described elsewhere.2 The sensitivity of the assay is 2 ng/ml and the interassay coefficient of variance is 7.5%.
PLASMA RENIN ACTIVITY Plasma renin activity was measured using the technique of Drury and Edwards.3 The range for normal supine subjects is 0-3-1*5 ng/ml/h. The coefficients of variance were 10% (intra-assay) and 18% (interassay).
Results
SHORT TERM RESPONSE
Haemodynamic response-Tabje 1 shows haemodynamic changes found after the first 25 mg dose of captopril. Systemic vascular resistance fell by 36% to reach a mean level just above the upper limit of the normal range. The percentage reduction in systemic vascular resistance for individual subjects ranged from 13% to 64%.
Plasma free captopnil-Captopril was absorbed rapidly with the peak concentration at 45 minutes after the dose. The rise in plasma free captopril coincided with the fall in systemic vascular resistance and was followed closely by an increase in plasma renin activity. Figure 1 shows the time profiles of changes in systemic vascular resistance, plasma free captopril concentration, and plasma renin activity in 10 patients. The areas under the four hour free captopril absorption curves varied from 44 to 689 mg/mI/h (mean (SD) 352 (237)).
Peak plasma free captopril concentrations varied appreciably, but there was no significant correlation ( Fig. 2) between the maximal percentage reduction in systemic vascular resistance and the peak plasma free captopril concentration (r=0-28) or its log concentration (r=0.40).
A small second peak of plasma free captopril concentration was seen in 16 of the 18 patients who had plasma free captopril concentrations measured up to four or 24 hours after the dose. The mean secondary rise was 38*1 mg/ml from a mean preceding concentration of 56-3 mg/ml. Of the eight subjects in whom plasma free captopril was measured for 24 hours, two had slow absorption with peak captopril concentrations at 90 and 240 minutes after the dose. The other six patients showed a rapid absorption of captopril (peak concentration <60 minutes after the dose); a small second peak was apparent at two hours in these subjects (Fig. 3) . The elimination rate of free captopril, measured from five to 24 hours after the dose in these six subjects, was seven hours. (Fig. 4) .
Haemodynamic response- Table 2 summarises the haemodynamic and non-invasive variables before and after 1-2 months of captopril treatment.
Plasma firee captopril-The dosage of captopril at repeat study ranged from 75 mg/day to 450 mg/day. The mean plasma concentrations for daily dosages of 75 (n=4), 150 (n= 7), and 300-450 mg (n=3) were 46, 73, and 233 ng/ml respectively. There was a significant correlation between dosage and free captopril concentration (r= 0 77, p<0C01). renin activity were measured throughout an eight hour dose interval during long term treatment in six patients. Two were receiving 25 mg three times daily and four 50 mg three times daily Figure 5 shows the results. The predose (0900 h) plasma free captopril concentration was low, and there was a pronounced rise in drug concentration after absorption of the dose, with a small second peak at six hours. Plasma renin activity showed a further increase after the dose.
Discussion
In individual cardiac patients the haemodynamic and symptomatic response to captopril can vary from minimal to very substantial. Our results, like other studies,' 4 5 show an overall moderate degree of improvement in symptoms, resting haemodynamic indices, and non-invasive indices of cardiac function, and they confirm the wide range of individual responses. Since this was an open study and a placebo period was not included the changes in symptom status have to be interpreted with caution. Similar benefits from captopril in heart failure have, however, been found in double blind controlled studies.68
Wide differences in peak plasma free captopril concentration were found but did not correlate with maximal percentage change in systemic vascular resistance. Plasma also contains captopril linked to the plasma proteins, cysteine and glutathione, and captopril molecules linked together as disulphide bond dimers,9 IO but these compounds are not thought to be biologically active. The lack of relation between maximal response and peak plasma free captopril concentration after a 25 mg oral dose may be explained by the flat dose-response relation found in incremental dose studies when captopril dose exceeded 6-25 mg. There was also no correlation between captopril concentration and long term response, and our results do not show any evidence that measurement of plasma free captopril concentration would be useful in monitoring response.
The (Fig. 1) . Levine et al also observed a small secondary peak in response. 13 The true elimination rate of a drug is often difficult to establish as the absorption and distribution phases can continue until the plasma drug concentration is too low for the sensitivity of the assay. This second peak complicates the estimation of the elimination rate of plasma free captopril, but when taken between 5 and 24 hours after the dose we found the log concentration time plot to be linear and the elimination half life to be seven hours.
We found that throughout an eight hour dose interval during long term treatment (25-50 mg three times daily) the plasma free captopril concentration was maintained at levels which had provided some 
